Autolus Therapeutics plc is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. The company's pipeline includes innovative CAR-T cell therapies designed to recognize and kill cancer cells, with a focus on hematological malignancies and solid tumors. Autolus aims to deliver transformative treatments by engineering T cells with enhanced precision, safety, and efficacy.
Serves as the central hub for corporate strategy, research leadership, clinical development oversight, financial operations, and administrative functions.
Located within The MediaWorks, a modern campus designed to foster collaboration and innovation, part of London's growing White City Innovation District.
A dynamic, science-driven environment focused on innovation, collaboration, and a commitment to advancing patient care. Employees are typically engaged in cutting-edge research and development with a strong sense of purpose.
The headquarters is pivotal for orchestrating Autolus's global operations, R&D efforts, and strategic partnerships, driving the development of its novel T cell therapies.
Autolus Therapeutics primarily operates from its key sites in the United Kingdom (London and Stevenage) and the United States (Rockville, MD). These locations support global research and development, clinical trial management across multiple countries, manufacturing of its cell therapies, and strategic corporate functions. While physical offices are concentrated, their clinical trials and collaborations extend internationally, giving them a functional global reach in the biopharmaceutical landscape.
The MediaWorks, 191 Wood Lane
London
White City
United Kingdom
Address: The Nucleus, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2FX, UK
Located in the Stevenage Bioscience Catalyst campus, a key UK hub for cell and gene therapy, providing access to specialized infrastructure and talent for advanced therapy manufacturing.
Address: 9800 Medical Center Drive, Suite C-120, Rockville, MD 20850, USA
Strategically positioned to access the US pharmaceutical market, engage with US regulatory authorities, and collaborate with leading US clinical research institutions.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Autolus Therapeutics' leadership includes:
Autolus Therapeutics has been backed by several prominent investors over the years, including:
Autolus Therapeutics has strengthened its executive team over the past year with key appointments in finance and commercial operations, including a new Chief Financial Officer and a new Chief Commercial Officer, positioning the company for its next phase of growth and potential commercialization.
Discover the tools Autolus Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Autolus Therapeutics plc likely uses common corporate email formats. The most probable patterns are [first_initial][lastname]@autolus.com or [first].[lastname]@autolus.com. For example, for an employee named Jane Doe, the email could be jdoe@autolus.com or jane.doe@autolus.com.
[first_initial][lastname]@autolus.com or [first].[lastname]@autolus.com
Format
j.doe@autolus.com
Example
80%
Success rate
Autolus Therapeutics plc • May 22, 2024
Autolus announced its financial results for Q1 2024, highlighting progress with its obe-cel BLA submission to the FDA and ongoing clinical development programs....more
Autolus Therapeutics plc • April 29, 2024
Autolus submitted its BLA for obecabtagene autoleucel (obe-cel) for adult patients with r/r B-ALL, a significant milestone for the company....more
Autolus Therapeutics plc • March 4, 2024
Autolus appointed Christopher Vann as CCO to lead its global commercial strategy and operations as it prepares for potential product commercialization....more
Autolus Therapeutics plc • January 29, 2024
Autolus announced its participation in several key investor conferences to provide business updates and discuss its pipeline progress....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Autolus Therapeutics, are just a search away.